乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

AHA

<乌鸦传媒>AHA: Targeting Inflammation With Methotrexate Flops for CV Prevention

CIRT trial disappoints after CANTOS' win for the inflammatory hypothesis

<乌鸦传媒>AHA: Prescription Fish Oil Wins for CV Prevention

Positive findings for Vascepa in REDUCE-IT trial

<乌鸦传媒>AHA: Revised Lipid Guide Boosts PCSK9s, Coronary Calcium Scans

New recommendations aim to cut statins in low-risk primary prevention

<乌鸦传媒>AHA: Lipid Guidelines to Headline Meeting

Exercise, fish oil, Entresto in acute HF, and an anti-inflammatory also in the spotlight

<乌鸦传媒>AHA: Late Meals Linked to HTN, Prediabetes

Risks seen in study of Hispanic and Latino Americans

<乌鸦传媒>AHA: ORBITA Debate Continues

Gersh, Mehran, Block, Yeh, Chazal, Bairey Merz, Brown, Eagle weigh in

<乌鸦传媒>'Safer' Cigarettes Still Prove Harmful to Blood Vessels

Heat-not-burn product impacts endothelial function in animal model

<乌鸦传媒>AHA: Everybody Now Is a Clinical Investigator, Says Califf

Time to revolutionize clinical data gathering, ex-FDA Commissioner urges

<乌鸦传媒>AHA: BP Measurement in SPRINT Was All Over the Place

Did varying presence of staff during BP readings ruin a huge study?

<乌鸦传媒>AHA: Follow Same HTN Cutoff for Adults and Teens

But adult and pediatric hypertension guidelines differ in other respects

<乌鸦传媒>AHA: Evolocumab's Absolute Benefit Greater in PAD Patients

Symptomatic PAD yields bigger bang for PCSK9 big bucks

<乌鸦传媒>Heart Attack Fells AHA President During Annual Meeting

The AHA reports that he received a stent and is doing well

<乌鸦传媒>AHA: 130/80 mm Hg Is New National BP Target

Multisociety guidelines released accounting for SPRINT data

<乌鸦传媒>AHA: Brief NOAC Interruption Safer Than Warfarin in Afib Ablation

Fewer major bleeds than with uninterrupted warfarin in Japanese trial

<乌鸦传媒>AHA: CANTOS Substudy Supports Major Role of Inflammation

Large reductions in hsCRP appeared to foretell improved outcomes

<乌鸦传媒>AHA: For CIED Surgery, NOAC Administration Up to Clinician

Continued or interrupted therapy carried same risk of clinically significant hematoma development

<乌鸦传媒>AHA: Restrictive Blood Transfusion OK for Select Patients

Stricter approach deemed noninferior to liberal strategy in cardiac surgery

<乌鸦传媒>AHA: ACA Program Offers Mixed Results for HF Readmits

HRRP tied to less readmissions, but seems to up mortality

<乌鸦传媒>Sex: Odds Are It Won't Kill You

But when it is fatal, the victim is likely to be male

<乌鸦传媒>Trial: No Benefit for High-Dose Diuretic in Acute HF

But phase II results might not be the final word

<乌鸦传媒>AHA: Mixed Results For ApoA-1 Therapies

But it's still not time to write the obituary for all HDL therapies

<乌鸦传媒>AHA: No Pump Thrombosis With Next-Gen LVAD?

Better outcomes in HeartMate 3 trial hinged on fewer malfunctions

<乌鸦传媒>AHA: Lower Better for Plaque Regression with PCSK9 Drugs

No diminishing returns at very low LDL levels in GLAGOV trial

<乌鸦传媒>AHA: Real World TAVR Is All About Patient Selection

Intermediate risk is a moving target

<乌鸦传媒>Statin 'Census' Shows Major Disparities

Women, minorities treated at significantly lower rates

<乌鸦传媒>AHA: Healthy Lifestyle Eases Heart Impact of High Genetic Risk

Fewer adverse events, less calcification in pooled data

<乌鸦传媒>AHA: No Cognitive Benefit from Heart Drugs in HOPE-3

Substudy finds mental function unimproved by BP, cholesterol treatments

<乌鸦传媒>AHA: Long-Term Benefit in HF Patients Elusive for Novel Vasodilator

Investigational drug ularitide had no effect on mortality or clinical outcomes

<乌鸦传媒>AHA: Study Finds Celebrex Safe for Heart

But naproxen not as heart safe as believed

<乌鸦传媒>AHA: Multiple Listers for Transplants: Longer Wait, Lower Mortality

Disparity of organs by region a factor

<乌鸦传媒>SPRINT v. ACCORD: Which Target Will Win in Diabetes?

Not such a no-brainer, hypertension experts say

<乌鸦传媒>AHA: 3D Imaging May Mean Better Match for Pediatric Hearts

"Virtual transplant" could maximize use of donor hearts

<乌鸦传媒>AHA: Long-Acting Nitrate Flops in HFpEF

Study does not support the use of nitrates in subgroup of heart failure patients

<乌鸦传媒>AHA: No Excess Bleeding Risk with Dabigatran

LOS ANGELES -- Patients starting dabigatran (Pradaxa) did not have a higher risk of bleeding compared with new users of warfarin, according to a postmarketing data review by the FDA.

<乌鸦传媒>AHA: One or Two Drinks May Not Hurt Bypass Patients

CHICAGO -- Having an alcoholic drink does not appear to cause problems for patients following coronary artery bypass graft surgery -- but doctors warn that these patients cannot have more than one or two drinks a day.

<乌鸦传媒>AHA: Rivaroxaban Scores Win While Omega-3 Flops

CHICAGO -- Good news and not so good news about investigational treatments for atrial fibrillation are featured in this exclusive InFocus video report from the American Heart Association meeting.

<乌鸦传媒>AHA: FDA Drops Clopidogrel Bomb at AHA

ORLANDO -- The FDA has issued a public health advisory warning patients and physicians that concommitant use of clopidogrel (Plavix) and omeprazole (Prilosec and Prilosec OTC) blunts the antiplatelet effect of clopidogrel, so the combination should be avoided.

<乌鸦传媒>AHA: Some Statins May Disrupt Sleep

ORLANDO -- If patients taking simvastatin (Zocor) develop sleep disturbances, changing statins may be a good idea, researchers suggested here.